Shots:

• The P-III (ARANOTE) trial evaluated the safety & efficacy of darolutamide (600mg, BID) + ADT vs PBO + ADT to treat mHSPC patients (n=669)
• Study reached its 1EP, showing increased rPFS & a safety profile that was similar across the two arms. Full data will be highlighted at the upcoming conferences and will be submitted to the regulatory authorities seeking its expanded use in mHSPC
• In addition, darolutamide is also being assessed in P-III (ARASTEP) trial combined with ADT vs ADT alone in high-risk BCR prostate cancer & P-III (DASL-HiCaP) trial as an adj. treatment for localized prostate cancer with a high risk of recurrence (led by the Australian & New Zealand Urogenital and Prostate Cancer Trials Group)

Ref: Bayer | Image: Bayer

Related News:- Orion’s Darolutamide Receives EC’s Marketing Authorisation for the Treatment of Prostate Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com